In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019

•Imipenem-relebactam demonstrated excellent in vitro activity versus Enterobacterales and P. aeruginosa clinical isolates obtained from patients across Canada as part of an ongoing, national surveillance study (CANWARD).•Excluding Serratia marcescens, 96.7% to 100% of Enterobacterales species were s...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic microbiology and infectious disease 2021-09, Vol.101 (1), p.115418-115418, Article 115418
Main Authors: Walkty, Andrew, Karlowsky, James A., Baxter, Melanie R., Adam, Heather J., Golden, Alyssa, Lagace-Wiens, Philippe, Zhanel, George G.
Format: Article
Language:English
Subjects:
Gram-negative bacteria
Imipenem
Imipenem-relebactam
Multidrug-resistant
Pseudomonas aeruginosa
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Imipenem-relebactam demonstrated excellent in vitro activity versus Enterobacterales and P. aeruginosa clinical isolates obtained from patients across Canada as part of an ongoing, national surveillance study (CANWARD).•Excluding Serratia marcescens, 96.7% to 100% of Enterobacterales species were susceptible to imipenem-relebactam (including ESBL-producing isolates and those with a MDR phenotype).•Susceptibility of all P. aeruginosa isolates and the subset of MDR P. aeruginosa isolates to imipenem-relebactam was 91.3% and 70.8%, respectively. Broth microdilution was used to determine the in vitro activities of imipenem-relebactam and comparators versus 4260 Enterobacterales and 1324 Pseudomonas aeruginosa clinical isolates. Excluding Serratia marcescens, 96.7% to 100% of Enterobacterales species were susceptible to imipenem-relebactam. Susceptibility of P. aeruginosa isolates to imipenem-relebactam and imipenem was 91.3% and 59.1%, respectively.
ISSN:0732-8893
1879-0070
DOI:10.1016/j.diagmicrobio.2021.115418